Compound details
tetrahydro-TPP
| Compound ID | CDAMM01855 |
|---|---|
| Common name | tetrahydro-TPP | IUPAC name | 2-[3-[(4-amino-2-methylpyrimidin-5-yl)methyl]-4-methyl-1,3-thiazolidin-5-yl]ethyl phosphono hydrogen phosphate |
| Molecular formula | C12H22N4O7P2S |
| Retention time | 19.01 |
|---|---|
| Adduct | [M+H]+ |
| Actual mz | 429.07 | Theoretical mz | 429.075 |
| Error | 11.83 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 6.2955 |
| Inchi key | QMLRZDVHAMEWFV-UHFFFAOYNA-N |
|---|---|
| Smiles | O=P(O)(O)OP(=O)(O)OCCC1SCN(CC2=CN=C(NC2=N)C)C1C |
| Superclass | Organic oxygen compounds |
| Class | Organic oxoanionic compounds |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P00491 | PNP | Purine nucleoside phosphorylase | T78198 | SwissTargetPrediction |
| P06746 | POLB | DNA polymerase beta (by homology) | T06958 | SEA |
| P29401 | TKT | Transketolase | T67754 | SEA |
| P41231 | P2RY2 | Purinergic receptor P2Y2 | T93515 | SEA |
| Q15077 | P2RY6 | Pyrimidinergic receptor P2Y6 | T90782 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T78198 | DI0120 | Diabetes mellitus | [ICD-11: 5A10] | P00491 | PNP |
| T78198 | DI0167 | Gout | [ICD-11: FA25] | P00491 | PNP |
| T78198 | DI0245 | Malignant haematopoietic neoplasm | [ICD-11: 2B33] | P00491 | PNP |
| T78198 | DI0283 | Mycosis fungoides | [ICD-11: 2B01] | P00491 | PNP |
| T78198 | DI0351 | Psoriasis | [ICD-11: EA90] | P00491 | PNP |
| T06958 | DI0391 | Solid tumour/cancer | [ICD-11: 2A00-2F9Z] | P06746 | POLB |
| T93515 | DI0436 | Visual system disease | [ICD-11: 9E1Z] | P41231 | P2RY2 |
| T90782 | DI0025 | Alzheimer disease | [ICD-11: 8A20] | Q15077 | P2RY6 |